{"schema_version":"secwatch.filing_event.v1","accession":"0001607062-21-000297","form_type":"8-K","ticker":"RGBP","cik":"0001589150","company_name":"Regen BioPharma Inc","filed_at":"2021-08-26T23:59:59+00:00","discovered_at":"2026-05-14T18:04:18.702663+00:00","generated_at":"2026-06-29T07:34:49.514604+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Regen Biopharma receives U.S. patent for mRNA-based cancer vaccine technology","bullets":["USPTO issued Patent No. 11,090,332 B2 on August 17, 2021, for \"Antigen Specific MRNA Cellular Cancer Vaccines\".","The invention covers modified mRNA encoding immunogenic epitopes, e.g., survivin-derived peptides, to induce intracellular antigen production.","Patent aims to expand epitope repertoire presented to adaptive immune system, improving likelihood of successful immunity induction."],"urls":{"canonical":"https://secwatch.observer/filing/0001607062-21-000297","json":"https://secwatch.observer/filing/0001607062-21-000297.json","markdown":"https://secwatch.observer/filing/0001607062-21-000297.md","text":"https://secwatch.observer/filing/0001607062-21-000297.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1589150/000160706221000297/0001607062-21-000297-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1589150/000160706221000297/rgbp082621form8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T07:34:49.514604+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}